MCID: MYT002
MIFTS: 48

Myotonic Dystrophy

Categories: Rare diseases, Genetic diseases, Neuronal diseases, Eye diseases, Reproductive diseases, Endocrine diseases, Muscle diseases

Aliases & Classifications for Myotonic Dystrophy

MalaCards integrated aliases for Myotonic Dystrophy:

Name: Myotonic Dystrophy 72 50 25 29 52 69
Dystrophia Myotonica 50 25
Myotonia Dystrophica 50 25
Myotonia Atrophica 50 25
Myotonic Dystrophy 1 69

Classifications:



Summaries for Myotonic Dystrophy

NIH Rare Diseases : 50 myotonic dystrophy is a disease that affects the muscles and other body systems. it is the most common form of muscular dystrophy that begins in adulthood, usually in a person’s 20s or 30s. this disease is characterized by progressive muscle loss and weakness. myotonic dystrophy may be further classified into two types, and the two types may affect different muscles. people with myotonic dystrophy usually have prolonged muscle tensing (myotonia) and are not able to relax certain muscles after use. the severity of the disease may vary among affected people, even among members of the same family. myotonic dystrophy is caused by mutations (changes) in the dmpk gene or the cnbp (znf9) gene depending on the specific type of myotonic dystrophy. the disease is inherited in an autosomal dominant manner. myotonic dystrophy may be diagnosed when a healthcare provider observes signs and symptoms of the disease, and the diagnosis may be confirmed with tests of muscle function and genetic testing. treatment is based on each person’s specific signs and symptoms and may include physical therapy, pain management with medication, and consultation with specialists.  last updated: 8/21/2017

MalaCards based summary : Myotonic Dystrophy, also known as dystrophia myotonica, is related to myotonic dystrophy 1 and myotonic dystrophy 2, and has symptoms including excessive daytime somnolence and weakness. An important gene associated with Myotonic Dystrophy is DMPK (Dystrophia Myotonica Protein Kinase). The drugs Dopamine and Lamotrigine have been mentioned in the context of this disorder. Affiliated tissues include testes, heart and skeletal muscle, and related phenotypes are Condensed cis-Golgi and Increased cell viability after pRB stimulation

Genetics Home Reference : 25 Myotonic dystrophy is part of a group of inherited disorders called muscular dystrophies. It is the most common form of muscular dystrophy that begins in adulthood.

Wikipedia : 72 Myotonic dystrophy is a long term genetic disorder that affects muscle function. Symptoms include... more...

Related Diseases for Myotonic Dystrophy

Diseases in the Myotonic Dystrophy family:

Myotonic Dystrophy 2 Myotonic Dystrophy 1

Diseases related to Myotonic Dystrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 158)
id Related Disease Score Top Affiliating Genes
1 myotonic dystrophy 1 12.5
2 myotonic dystrophy 2 12.5
3 dysphagia 11.2
4 colorectal adenomatous polyposis, autosomal recessive, with pilomatricomas 10.9
5 myotonia atrophica 10.9
6 floppy infant syndrome 10.9
7 hypotonia 10.9
8 infantile hypotonia 10.9
9 swallowing disorders 10.9
10 myotonia 10.4
11 myopathy 10.3
12 muscular dystrophy 10.2
13 neuropathy 10.2
14 cerebritis 10.2
15 cataract 10.1
16 atrial fibrillation 10.1
17 hypersomnia 10.1
18 sleep disorder 10.1
19 neuronitis 10.1
20 myotonia congenita 10.0
21 polyhydramnios 10.0
22 cardiomyopathy 10.0
23 ataxia 10.0
24 myasthenia gravis 10.0
25 hypogonadism 10.0
26 muscular atrophy 10.0
27 sudden cardiac death 10.0
28 endotheliitis 10.0
29 fragile x syndrome 9.9
30 duchenne muscular dystrophy 9.9
31 becker muscular dystrophy 9.9
32 hydrocephalus 9.9
33 restless legs syndrome 9.9
34 cholelithiasis 9.9
35 respiratory failure 9.9
36 epilepsy 9.9
37 thymoma 9.9
38 laryngitis 9.9
39 intestinal pseudo-obstruction 9.9
40 neuromuscular disease 9.9
41 talipes equinovarus 9.9
42 cerebral palsy 9.8
43 liver disease 9.8
44 spinal muscular atrophy 9.8
45 asperger syndrome 9.8
46 sleep apnea 9.8
47 glucose intolerance 9.8
48 megacolon 9.8
49 esophagitis 9.8
50 cholestasis 9.8

Graphical network of the top 20 diseases related to Myotonic Dystrophy:



Diseases related to Myotonic Dystrophy

Symptoms & Phenotypes for Myotonic Dystrophy

UMLS symptoms related to Myotonic Dystrophy:


excessive daytime somnolence, weakness

GenomeRNAi Phenotypes related to Myotonic Dystrophy according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Condensed cis-Golgi GR00365-A 9.13 CDC42BPA CKM DMPK
2 Increased cell viability after pRB stimulation GR00230-A-1 8.92 CDC42BPA CDC42BPB CKM DMPK

MGI Mouse Phenotypes related to Myotonic Dystrophy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.23 ATP2A1 CKM CLCN1 DMPK MBNL1 MBNL2

Drugs & Therapeutics for Myotonic Dystrophy

Drugs for Myotonic Dystrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 54)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 2, Phase 3 51-61-6, 62-31-7 681
2
Lamotrigine Approved, Investigational Phase 3 84057-84-1 3878
3
Methylphenidate Approved, Investigational Phase 2, Phase 3 113-45-1 4158
4
Fesoterodine Approved Phase 3 286930-02-7, 286930-03-8 6918558
5
Dehydroepiandrosterone Approved, Nutraceutical Phase 2, Phase 3 53-43-0 9860744
6 Acyclovir Phase 3
7 calcium channel blockers Phase 3
8 Adjuvants, Immunologic Phase 2, Phase 3
9 Central Nervous System Stimulants Phase 2, Phase 3
10 Cholinergic Agents Phase 3
11 Muscarinic Antagonists Phase 3
12 Cholinergic Antagonists Phase 3
13 Sodium Channel Blockers Phase 3,Phase 2
14 Neurotransmitter Agents Phase 2, Phase 3
15 Neurotransmitter Uptake Inhibitors Phase 2, Phase 3
16 Diuretics, Potassium Sparing Phase 3,Phase 2
17 Dopamine Agents Phase 2, Phase 3
18 Dopamine Uptake Inhibitors Phase 2, Phase 3
19 Anti-Infective Agents Phase 3
20 Excitatory Amino Acid Antagonists Phase 3
21 Excitatory Amino Acids Phase 3
22 Anticonvulsants Phase 3
23 Calcium, Dietary Phase 3
24 Antiviral Agents Phase 3
25 DHEA (Dehydroepiandrosterone) Nutraceutical Phase 2, Phase 3
26
Zinc Approved Phase 2 7440-66-6 32051 23994
27
Mexiletine Approved Phase 2 31828-71-4 4178
28
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
29
Leuprolide Approved, Investigational Phase 2 53714-56-0 3911 657181
30
Exemestane Approved, Investigational Phase 2 107868-30-4 60198
31
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
32
Anastrozole Approved, Investigational Phase 2 120511-73-1 2187
33
Pertuzumab Approved Phase 2 145040-37-5, 380610-27-5 2540
34
Ranolazine Approved, Investigational Phase 2 142387-99-3, 95635-55-5 56959
35 insulin Phase 2,Phase 1
36 Mitogens Phase 2,Phase 1
37 Complement Factor I Phase 2
38 Hypoglycemic Agents Phase 2
39 Insulin, Globin Zinc Phase 2,Phase 1
40 Anti-Arrhythmia Agents Phase 2
41 Fertility Agents Phase 2
42 Steroid Synthesis Inhibitors Phase 2
43 Hormone Antagonists Phase 2
44 Hormones Phase 2
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
46 Estrogen Antagonists Phase 2
47 Estrogens Phase 2
48 Immunoglobulins Phase 2
49 Antibodies, Monoclonal Phase 2
50 Prolactin Release-Inhibiting Factors Phase 2

Interventional clinical trials:

(show all 48)

id Name Status NCT ID Phase Drugs
1 RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic Dystrophy Unknown status NCT00127582 Phase 3
2 Efficacy and Safety of DHEA for Myotonic Dystrophy Completed NCT00167609 Phase 2, Phase 3 dehydroepiandrosterone 100 and 400 mg
3 Methylphenidate in Myotonic Dystrophy Type 1 Completed NCT01421992 Phase 2, Phase 3 Methylphenidate;Placebo
4 Lamotrigine as Treatment of Myotonia Completed NCT01939561 Phase 3 Lamotrigine;Placebo
5 Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome Completed NCT00220402 Phase 3 SPM 907
6 A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome Completed NCT00220363 Phase 3 SPM 907
7 Safety and Efficacy of a Violet Visible Light Blocking Intraocular Lens (IOL) Completed NCT00747227 Phase 3
8 PD P 506 A-PDT Versus Placebo-PDT and Cryosurgery for the Treatment of AK Completed NCT00308867 Phase 3
9 Phase 3 Clinical Study for the Treatment of Cold Sore Completed NCT00769314 Phase 3 Acyclovir Lauriad;Placebo
10 Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive Active, not recruiting NCT01225614 Phase 3
11 Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1 Unknown status NCT00577577 Phase 2 rhIGF-I/rhIGFBP-3;placebo
12 Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1 Completed NCT01406873 Phase 2 Mexiletine;Placebo
13 Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1) Completed NCT00233519 Phase 1, Phase 2 SomatoKine/IPLEX
14 A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1 Completed NCT02312011 Phase 1, Phase 2 IONIS-DMPKRx;Placebo
15 Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1 Recruiting NCT02251457 Phase 2 Ranolazine
16 NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer Recruiting NCT02689921 Phase 2 Exemestane;Letrozole;Anastrozole;Leuprolide Acetate;Pertuzumab;Trastuzumab
17 Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy Active, not recruiting NCT02858908 Phase 2 Tideglusib
18 The Efficacy of Using Far Infrared Radiation to Manage Muscular Dystrophies Unknown status NCT00674843 Phase 1
19 Intramuscular Transplantation of Muscle Derived Stem Cell and Adipose Derived Mesenchymal Stem Cells in Patients With Facioscapulohumeral Dystrophy (FSHD) Recruiting NCT02208713 Phase 1
20 Children's Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy Unknown status NCT02269865
21 Cardiovascular Consequences of NIV Withdrawal in Patients With Myotonic Dystrophy Unknown status NCT00745238
22 Tracking the Brain in Myotonic Dystrophies: a 5-year Longitudinal Follow-up Study Completed NCT02729597
23 Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients Completed NCT01242007
24 Observational Prolonged Trial in Myotonic Dystrophy Type 1 Completed NCT02118779
25 Multicenter Observational Study of Myotonic Dystrophy Type 1 Completed NCT02308657
26 Study of Muscle Wasting and Altered Metabolism in Patients With Myotonic Dystrophy Completed NCT00004769
27 DM1 Heart Registry - DM1 Respiratory Registry Completed NCT01136330
28 Efficacy and Tolerance of AVAPS Mode in Myotonic Dystrophy Completed NCT01530841
29 Venous Thromboembolism in DM1 Completed NCT03141749
30 Quality of Life in Neuromuscular Disease Completed NCT02895763
31 PhenoDM1 (Myotonic Dystrophy Type 1 Natural History Study) Recruiting NCT02831504
32 Trial Readiness and Endpoint Assessment in Congenital Myotonic Dystrophy Recruiting NCT03059264
33 Myotonic Dystrophy Family Registry Recruiting NCT02398786
34 Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy Recruiting NCT02880735
35 Sleep Breathing Disorders, a Main Trigger for Cardiac ARythmias in Type I Myotonic Dystrophy ? Recruiting NCT02375087
36 Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry Recruiting NCT00082108
37 Non Invasive Prenatal Testing (NIPT) of Single-gene Disorders Recruiting NCT02339402
38 Screening Questionnaire for Respiratory Muscle Weakness and Sleep-disordered Breathing in Neuromuscular Disorders Recruiting NCT02833168
39 Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis Recruiting NCT02934477
40 Arrhythmias in Myotonic Muscular Dystrophy Active, not recruiting NCT00622453
41 An MRI Study on Muscular Diseases -Pompe Disease and Dystrophia Myotonica- Enrolling by invitation NCT02708784
42 Muscle Relaxation in Myopathies With Positive Muscle Phenomena Enrolling by invitation NCT03211923
43 Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias Enrolling by invitation NCT02413450
44 NIPD on CFTC for Triplet Repeat Diseases Not yet recruiting NCT03087526
45 Compare Train and 3D-4D Left Ventricular Systolic Function in Subjects Suffering From Dystrophy and Healthy Subjects Terminated NCT02930408
46 Development of New Prenatal Diagnostic Tests From Maternal Blood Terminated NCT00314691
47 European Home Mechanical Ventilation Registry Terminated NCT02315339
48 A Clinical Trial to Evaluate the Safety and Effectiveness of the Raindrop Near Vision Inlay for Pseudophakic Subjects Terminated NCT03017612

Search NIH Clinical Center for Myotonic Dystrophy

Genetic Tests for Myotonic Dystrophy

Genetic tests related to Myotonic Dystrophy:

id Genetic test Affiliating Genes
1 Myotonic Dystrophy 29

Anatomical Context for Myotonic Dystrophy

MalaCards organs/tissues related to Myotonic Dystrophy:

39
Testes, Heart, Skeletal Muscle, Brain, Breast, Liver, Lung

Publications for Myotonic Dystrophy

Articles related to Myotonic Dystrophy:

(show top 50) (show all 1301)
id Title Authors Year
1
Personality traits in patients with myotonic dystrophy type 2. ( 28690389 )
2017
2
Corneal Endothelial Dystrophy Associated With Myotonic Dystrophy: A Report of 2 Cases. ( 28820792 )
2017
3
Fuchs' Endothelial Corneal Dystrophy and RNA Foci in Patients With Myotonic Dystrophy. ( 28886202 )
2017
4
High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2. ( 28855409 )
2017
5
Cognitive decline over time in adults with myotonic dystrophy type 1: A 9-year longitudinal study. ( 27919548 )
2017
6
Comments on Letter to the Editor entitled: "Role of electrophysiological evaluation for the best device choice to prevent sudden cardiac death in patients with Myotonic Dystrophy Type1 and Emery Dreifuss Muscular Dystrophy". ( 28291654 )
2017
7
Preferential changes of skeletal muscle echogenicity in myotonic dystrophy type 1. ( 27933692 )
2017
8
Myotonic dystrophy: candidate small molecule therapeutics. ( 28780071 )
2017
9
Micro-RNA expression in muscle and fiber morphometry in myotonic dystrophy type 1. ( 28078570 )
2017
10
Evolving Motivations: Patients' and Caregivers' Perceptions About Seeking Myotonic Dystrophy (DM1) and Huntington's Disease Care. ( 28799481 )
2017
11
Structure and Dynamics of RNA Repeat Expansions That Cause Huntington's Disease and Myotonic Dystrophy Type 1. ( 28617590 )
2017
12
Congenital myotonic dystrophy-an RNA-mediated disease across a developmental continuum. ( 28717044 )
2017
13
The Myotonic Dystrophy Health Index: Italian validation of a disease-specific outcome measure. ( 28890289 )
2017
14
Disrupted prenatal RNA processing and myogenesis in congenital myotonic dystrophy. ( 28698297 )
2017
15
Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I. ( 28067669 )
2017
16
Receptor and post-receptor abnormalities contribute to insulin resistance in myotonic dystrophy type 1 and type 2 skeletal muscle. ( 28915272 )
2017
17
CpG Methylation, a Parent-of-Origin Effect for Maternal-Biased Transmission of Congenital Myotonic Dystrophy. ( 28257691 )
2017
18
BNA(NC) Gapmers Revert Splicing and Reduce RNA Foci with Low Toxicity in Myotonic Dystrophy Cells. ( 28853853 )
2017
19
Role of electrophysiological evaluation for the best device choice to prevent sudden cardiac death in patients with Myotonic Dystrophy Type 1 and Emery Dreifuss Muscular Dystrophy. ( 28237579 )
2017
20
Investigation of the molecular mechanisms underlying myotonic dystrophy types 1 and 2 cataracts using microRNAa89target gene networks. ( 28731161 )
2017
21
The proposal of a clinical protocol to assess central and peripheral fatigue in myotonic dystrophy type 1. ( 28715597 )
2017
22
Myotonic Dystrophy Type 1 Clinical, Electrophysiological and Molecular Characterization: Experience at Tertiary Care Centre. ( 28782311 )
2017
23
The cognitive profile of myotonic dystrophy type 1:A A systematic review and meta-analysis. ( 28892766 )
2017
24
RAN Translation Regulated by Muscleblind Proteins in Myotonic Dystrophy Type 2. ( 28910618 )
2017
25
Hyperostosis Frontalis Interna in Myotonic Dystrophy. ( 28824073 )
2017
26
Antisense transcription of the myotonic dystrophy locus yields low-abundant RNAs with and without (CAG)n repeat. ( 28102759 )
2017
27
Molecular genetic and clinical characterization of myotonic dystrophy type 1 patients carrying variant repeats within DMPK expansions. ( 28942489 )
2017
28
Clinical characteristics of pregnancies complicated by congenital myotonic dystrophy. ( 28791262 )
2017
29
Brain imaging in myotonic dystrophy type 1: A systematic review. ( 28768849 )
2017
30
Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects. ( 28078562 )
2017
31
Major involvement of trunk muscles in myotonic dystrophy type 1. ( 26984572 )
2016
32
Splicing misregulation of SCN5A contributes to cardiac-conduction delay and heart arrhythmia in myotonic dystrophy. ( 27063795 )
2016
33
Drug resistant focal epilepsy in a patient with myotonic dystrophy type 2: casual or causal association? ( 27225277 )
2016
34
Redox imbalance in peripheral blood of type 1 myotonic dystrophy patients. ( 26817806 )
2016
35
Myotonic Dystrophy Type 1 with Syringomyelia in a Young Patient. ( 26879026 )
2016
36
Renal dysfunction can be a common complication in patients with myotonic dystrophy 1. ( 27538647 )
2016
37
Myotonic dystrophy type 1: frequency of ophthalmologic findings. ( 27050845 )
2016
38
Two Cases of Endometrial Cancer in Twin Sisters with Myotonic Dystrophy. ( 27595026 )
2016
39
Genome therapy of myotonic dystrophy type 1 iPS cells for development of autologous stem cell therapy. ( 27203440 )
2016
40
Ritodrine-induced rhabdomyolysis, infantile myotonic dystrophy, and maternal myotonic dystrophy unveiled. ( 27987333 )
2016
41
Cutaneous features of myotonic dystrophy types 1 and 2: Implication of premature aging and vitamin D homeostasis. ( 28065683 )
2016
42
Atrial flutter in myotonic dystrophy type 1: Patient characteristics and clinical outcome. ( 26948709 )
2016
43
Neuromuscular transmission abnormalities in myotonic dystrophy type 1: A neurophysiological study. ( 27611986 )
2016
44
Myotonic dystrophy type 2 presenting as inflammatory myopathy. ( 27625258 )
2016
45
Knowledge of Sub-Types Important to Understanding of the Prevalence of Myotonic Dystrophy. ( 26974673 )
2016
46
Muscle MRI of the Upper Extremity in the Myotonic Dystrophy Type 1. ( 27466802 )
2016
47
Unravelling the myotonic dystrophy type 1 clinical spectrum: A systematic registry-based study with implications for disease classification. ( 27665240 )
2016
48
Body composition and clinical outcome measures in patients with myotonic dystrophy type 1. ( 28082208 )
2016
49
Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1. ( 27941019 )
2016
50
Clusters of cognitive impairment among different phenotypes of myotonic dystrophy type 1 and type 2. ( 27896491 )
2016

Variations for Myotonic Dystrophy

Expression for Myotonic Dystrophy

Search GEO for disease gene expression data for Myotonic Dystrophy.

Pathways for Myotonic Dystrophy

GO Terms for Myotonic Dystrophy

Cellular components related to Myotonic Dystrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.7 CDC42BPA CDC42BPB CELF1 CKM CNBP DMPK
2 sarcoplasmic reticulum GO:0016529 9.32 ATP2A1 DMPK
3 cell leading edge GO:0031252 9.26 CDC42BPA CDC42BPB
4 sarcoplasmic reticulum membrane GO:0033017 9.16 ATP2A1 DMPK
5 actomyosin GO:0042641 8.62 CDC42BPA CDC42BPB

Biological processes related to Myotonic Dystrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mRNA processing GO:0006397 9.46 CELF1 MBNL1 MBNL2 MBNL3
2 actin cytoskeleton reorganization GO:0031532 9.37 CDC42BPA CDC42BPB
3 actomyosin structure organization GO:0031032 9.32 CDC42BPA CDC42BPB
4 RNA splicing GO:0008380 9.26 CELF1 MBNL1 MBNL2 MBNL3
5 actin cytoskeleton organization GO:0030036 8.96 CDC42BPB
6 regulation of RNA splicing GO:0043484 8.92 CELF1 MBNL1 MBNL2 MBNL3

Molecular functions related to Myotonic Dystrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 9.28 ATP2A1 CDC42BPA CDC42BPB CNBP DMPK MBNL1

Sources for Myotonic Dystrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....